MedTrace Logo

Peripheral Dopamine in Postural Tachycardia Syndrome

NCT00685919 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-01-24

Study results available
· View outcomes & findings →

Summary

The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients with postural tachycardia syndrome (POTS). We will test the null hypothesis (Ho) that the effects of oral carbidopa administration on urinary sodium excretion will not differ between patients with POTS and healthy volunteers.

Conditions

  • Postural Tachycardia Syndrome
  • Orthostatic Intolerance

Interventions

DRUG

Carbidopa

200 mg every 6 hours for 5 doses given orally

DRUG

Placebo

every 6 hours for 5 doses, given orally, and matching Carbidopa

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Alfredo J Gamboa, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2020-07-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685919 on ClinicalTrials.gov